Qualigen Therapeutics Stock Forecast, Price & News

-0.47 (-18.08 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $2.13
50-Day Range
MA: $3.03
52-Week Range
Now: $2.13
Volume2.53 million shs
Average Volume1.53 million shs
Market Capitalization$49.12 million
P/E RatioN/A
Dividend YieldN/A
Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
Qualigen Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:QLGN
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value($1.13) per share


Net Income$-1,670,000.00


Market Cap$49.12 million
Next Earnings Date5/7/2021 (Estimated)
OptionableNot Optionable


Insider Buys Qualigen Therapeutics Stock
December 30, 2020 |
QLGN: Testing AS1411 as COVID-19 Treatment…
November 30, 2020 |
Qualigen Therapeutics, Inc. Common Stock (QLGN)
November 3, 2020 |
See More Headlines


Overall MarketRank

1.13 out of 5 stars

Medical Sector

972nd out of 2,016 stocks

Pharmaceutical Preparations Industry

457th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.47 (-18.08 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QLGN News and Ratings via Email

Sign-up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Qualigen Therapeutics (NASDAQ:QLGN) Frequently Asked Questions

Is Qualigen Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Qualigen Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Qualigen Therapeutics stock.
View analyst ratings for Qualigen Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Qualigen Therapeutics?

Wall Street analysts have given Qualigen Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Qualigen Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Qualigen Therapeutics' next earnings date?

Qualigen Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 7th 2021.
View our earnings forecast for Qualigen Therapeutics

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) issued its quarterly earnings data on Thursday, November, 19th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.31. The business had revenue of $0.84 million for the quarter, compared to analysts' expectations of $1.40 million.
View Qualigen Therapeutics' earnings history

Who are Qualigen Therapeutics' key executives?

Qualigen Therapeutics' management team includes the following people:
  • Mr. Michael S. Poirier, Chairman, CEO & Pres (Age 65)
  • Mr. Christopher L. Lotz, VP of Fin. & CFO (Age 56)
  • Mr. Shishir K. Sinha, VP of Operations & Corp. Sec. (Age 53)
  • Dr. Wajdi Abdul-Ahad, VP of R&D and Chief Scientific Officer (Age 68)
  • Ms. Amy S. Broidrick, Exec. VP, Chief Strategy Officer & Director

Who are some of Qualigen Therapeutics' key competitors?

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qualigen Therapeutics investors own include iBio (IBIO), The Boeing (BA), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), NIO (NIO), NVIDIA (NVDA), Riot Blockchain (RIOT), Vaxart (VXRT), Boxlight (BOXL) and Enphase Energy (ENPH).

What is Qualigen Therapeutics' stock symbol?

Qualigen Therapeutics trades on the NASDAQ under the ticker symbol "QLGN."

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qualigen Therapeutics' stock price today?

One share of QLGN stock can currently be purchased for approximately $2.13.

How much money does Qualigen Therapeutics make?

Qualigen Therapeutics has a market capitalization of $49.12 million. The company earns $-1,670,000.00 in net income (profit) each year or ($26.50) on an earnings per share basis.

What is Qualigen Therapeutics' official website?

The official website for Qualigen Therapeutics is

Where are Qualigen Therapeutics' headquarters?

Qualigen Therapeutics is headquartered at 2042 Corte Del Nogal, Carlsbad CA, 92011.

How can I contact Qualigen Therapeutics?

Qualigen Therapeutics' mailing address is 2042 Corte Del Nogal, Carlsbad CA, 92011. The company can be reached via phone at 760-918-9165 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.